News

New recommendations for managing AAV released by EULAR

The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based on new research and clinical data. Four overarching principles were introduced — the importance of patient-physician joint decisions, disease education, routine screening for treatment side effects and additional medical conditions,…

Aneurysms more common in GPA than other AAV types: Study

People with granulomatosis with polyangiitis (GPA) are more likely to develop an aneurysm — a bulge in a blood vessel wall that can burst or rupture — than those with other types of ANCA-associated vasculitis (AAV), according to a small study in France. Aneurysms mainly affected medium-sized vessels, especially…

Eye symptoms seen in one-third of GPA patients in Italian study

More than one-third of people with granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis, may experience eye symptoms, a study in Italy has found. In many cases, eye symptoms were present from the onset of disease, sometimes even preceding more specific symptoms affecting other body parts. “Patients should…

Most AAV patients have fatigue severe enough to be a disorder

Many people with ANCA-associated vasculitis (AAV) have profound fatigue that’s severe enough to fulfill the diagnostic criteria for chronic fatigue syndrome, even when the disease isn’t active, a study shows. “We emphasize that physicians should be aware of this when assessing treatment and management strategies for improving quality…

Tavneos’ use by AAV patients prior to approval support its safety

Tavneos (avacopan) was generally safe and well tolerated in adults with severe ANCA-associated vasculitis treated under a global early access program (EAP) before the therapy’s approval, a study showed. EAPs make investigational therapies available outside clinical trials to people with serious or life-threatening conditions who have few or no…

Higher PR3-related AAV relapse risk may be tied to gene mutation

A gene variant linked to increased production of proteinase-3 (PR3) — one of the targets of disease-causing antibodies in ANCA-associated vasculitis (AAV) — is more common among patients with anti-PR3 antibodies than those with antibodies against the myeloperoxidase (MPO) protein, a study showed. The higher blood PR3 levels with this…